Unlabelled: This study investigated differences in prevalence of the androgen-regulated transmembrane protease serine 2 (TMPRSS2) and ETS transcription factor family member, v-ets erythroblastosis virus E26 oncogene homolog (ERG) fusion gene (TMPRSS2-ERG fusions) in clinically localized prostate cancer Japanese and German patients. A total of 105 specimens, including 69 Japanese and 36 German patients, were collected. The status of TMPRSS2-ERG fusion was determined by fluorescence in situ hybridization, and correlations of the TMPRSS2-ERG fusion with clinicopathological characteristics and immunohistochemistry were studied. Gene fusions were identified in 20% (14/69) of Japanese and 53% (19/36) of German patients (P < 0.001). The difference in the type of gene fusion between the two ethnic groups was statistically significant (P=0.024). Overexpression of ERG protein was significantly associated with gene fusion. Biochemical recurrence was significantly higher in patients with ERG overexpression than in those without, and not related to TMPRSS2-ERG fusion status. Interestingly, two types of gene fusions (deletion and increase of copy number) were significantly associated with increased p53 expression (P = 0.005). Association of specific gene fusions harboring higher genomic alterations with p53 expression levels suggests that p53 mutation might drive more aggressive arrangements of TMPRSS2-ERG fusion in prostate cancer.
Keywords: ERG, p53, prostate cancer, TMPRSS2-ERG fusion.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4149/neo_2015_033 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Unveiling the molecular profile of a prostate carcinoma: implications for personalized medicine.
Biol Direct
December 2024
Urology Unit, Department of Surgery, Tor Vergata University of Rome, Rome, Italy.
Background: Prostate cancer is the most common diagnosed tumor and the fifth cancer related death among men in Europe. Although several genetic alterations such as ERG-TMPRSS2 fusion, MYC amplification, PTEN deletion and mutations in p53 and BRCA2 genes play a key role in the pathogenesis of prostate cancer, specific gene alteration signature that could distinguish indolent from aggressive prostate cancer or may aid in patient stratification for prognosis and/or clinical management of patients with prostate cancer is still missing. Therefore, here, by a multi-omics approach we describe a prostate cancer carrying the fusion of TMPRSS2 with ERG gene and deletion of 16q chromosome arm.
View Article and Find Full Text PDFEtiology of prostate cancer with the TMPRSS2:ERG fusion: A systematic review of risk factors.
Int J Cancer
December 2024
Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, USA.
The most common somatic alteration in primary prostate cancer is the TMPRSS2:ERG gene fusion, which may be caused or promoted by distinct etiologic factors. The objective of this systematic review was to assess epidemiologic evidence on etiologic factors for prostate cancer by tumor TMPRSS2:ERG fusion status in human populations. Of 3071 publications identified, 19 cohort or case-control studies from six distinct study populations were included in this systematic review.
View Article and Find Full Text PDFMechanistic Insights and Molecular Diagnostics of TMPRSS2-ERG: Overview of the Journey from Regulation of Signaling Landscape in Fusion Positive Prostate Cancer to Appraisal as a Diagnostic Marker.
Front Biosci (Landmark Ed)
September 2024
Department of Anesthesiology, Reanimatology and Narcology, Semey Medical University, 071400 Semey, Republic of Kazakhstan.
Chromosomal rearrangements and recurrent gene fusions were previously presumed to be the primary oncogenic mechanisms of hematological malignancies. However, the discovery of gene fusions in different cancers has opened new horizons to comprehensively investigate how cell type-specific fusion oncoproteins modulate signaling cascades. Prostate cancer (PCa) is a multifaceted and therapeutically challenging disease, and functional genomics have helped us develop a better understanding of the mechanisms underlying prostate carcinogenesis, castration-resistant PCa, and metastasis.
View Article and Find Full Text PDFFrom microscopes to molecules: The evolution of prostate cancer diagnostics.
Cytojournal
August 2024
Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
In the ever-evolving landscape of oncology, the battle against prostate cancer (PCa) stands at a transformative juncture, propelled by the integration of molecular diagnostics into traditional cytopathological frameworks. This synthesis not only heralds a new epoch of precision medicine but also significantly enhances our understanding of the disease's genetic intricacies. Our comprehensive review navigates through the latest advancements in molecular biomarkers and their detection technologies, illuminating the potential these innovations hold for the clinical realm.
View Article and Find Full Text PDFGene Fusion Might Predict Resistance to PARP Inhibitors in Metastatic Castration-resistant Prostate Cancer.
Anticancer Res
October 2024
Molecular Unit, Department of Pathology, Herlev Hospital, Herlev, Denmark.
Article Synopsis
- The study investigates DNA damage repair (DDR) pathways and their impact on treating metastatic castration-resistant prostate cancer (mCRPC), especially focusing on poly ADP ribose polymerase (PARP) inhibitors (PARPi).
- Out of 114 patients, specific gene alterations were linked to varying responses to PARPi, showing that those without the TMPRSS2:ERG gene fusion and with certain homozygous alterations benefitted more from the treatment.
- The findings suggest that the presence of the TMPRSS2:ERG fusion may indicate resistance to PARPi, indicating its potential as a biomarker for treatment outcomes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!